• Capecitabine in Patient-Matched Cancer Assays

  2026-08-14

  Capecitabine is a fluoropyrimidine prodrug whose apparent selectivity can change when tumor cells are tested with patient-matched stroma. This guide translates a gastric cancer assembloid study into practical assay decisions for mechanistic preclinical oncology research.

• Triacetin Workflows for Oncology and Metabolism

  2026-08-13

  Triacetin, also called glyceryl triacetate, supports practical workflows spanning glioblastoma apoptosis studies, metabolic regulation, and ocular formulation screening. This guide connects concentration selection, formulation controls, and troubleshooting to help researchers distinguish compound biology from vehicle or assay artifacts.

• MK-2206: An AKT Counterprobe for Neurobiology

  2026-08-13

  MK-2206 dihydrochloride offers a precise way to test whether AKT signaling controls oxidative stress, neuronal injury, and microglial inflammation. This article develops a cross-domain assay strategy grounded in recent Parkinson’s disease research rather than repeating standard cancer apoptosis workflows.

• DAPI (hydrochloride): Practical Staining Guide

  2026-08-12

  DAPI (hydrochloride), also called 4',6-diamidino-2-phenylindole hydrochloride, provides a DNA-focused fluorescent readout for fixed-cell imaging, chromosome staining, histochemistry, and flow cytometry. This guide covers solvent selection, sample handling, controls, and troubleshooting; ethanol-based preparation and long-term storage of solutions should be avoided.

• Lysozyme–Amikacin Binding: Methods and Findings

  2026-08-12

  A January 2024 study combined tritium probing, fluorescence spectroscopy, interfacial measurements, enzymatic assays, and molecular docking to map how amikacin and levofloxacin interact with lysozyme. The results show that both ligands preserve lysozyme secondary structure, while amikacin nearly abolishes enzymatic activity and levofloxacin leaves key catalytic residues functionally unaffected.

• PA-824: From Nitro Reduction to TB Regimens

  2026-08-11

  PA-824 is more than a potent bicyclic nitroimidazole derivative: it is a mechanistic probe for understanding how cell-wall disruption, nitric oxide release, and respiratory collapse can be coordinated into more effective tuberculosis regimens. This article translates recent terminal-oxidase findings into practical research strategy, assay design, and translational decision-making.

• PD-L1–IL-6 Crosstalk in Primary Sclerosing Cholangitis

  2026-08-10

  Orlandi and colleagues combine spatial proteomics with cell–cell cross-talk analysis to define how PD-L1 and IL-6 signaling are organized at the epithelial–immune interface in human primary sclerosing cholangitis. The work provides a spatially informed framework for testing cytokine–checkpoint interactions, while also emphasizing that inferred communication requires functional validation.

• Protease Inhibitor Cocktail for MS-Safe Extraction

  2026-08-09

  Build cleaner cell and tissue lysates for immunoblotting, co-immunoprecipitation, and mass spectrometry with broad protease protection and no AEBSF. This workflow also shows how to preserve CYR61-related protein signals when studying irradiated BMSCs, migrasomes, migration, and osteogenic differentiation.

• From RNA Structure to Translational Signal

  2026-08-08

  A mechanistic and strategic guide to strengthening circRNA, miRNA, and mRNA measurements in bronchopulmonary dysplasia research with HyperScript™ RT SuperMix for qPCR.

• ER Stress and Intestinal Stem Cell Loss

  2026-08-07

  This study identifies a GRP78/ATF6/CHOP-centered response as a mechanism linking tunicamycin-induced endoplasmic reticulum stress to intestinal stem-cell depletion, impaired differentiation, and epithelial injury. Its integrated analysis of tissue morphology, stem-cell populations, apoptosis, proliferation, and p44/42 MAPK signaling provides a useful framework for studying how unresolved ER stress disrupts intestinal renewal.

• Lumiracoxib and the Duality of COX-2 in Muscle Repair

  2026-08-07

  Explore how Lumiracoxib, a selective COX-2 inhibitor, is transforming translational research on muscle regeneration and vascular repair. Drawing on recent mechanistic studies of venom-induced injury, this article offers strategic guidance for assay design and highlights the nuanced, time-dependent roles of COX-2 modulation in tissue ischemia and revascularization. Leveraging both product intelligence and frontier research, we bridge biological insight with actionable workflow recommendations for translational investigators.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist in Metabolic Rese

  2026-08-06

  Dehydroabietic acid stands out as a dual PPAR-α/γ agonist, enabling precise modulation of lipid metabolism and insulin sensitivity in metabolic disorder research. This guide distills advanced workflow strategies, troubleshooting insights, and direct protocol recommendations to maximize reproducibility and data quality.

• Losartan (SKU B1072): Reliable AT1 Antagonist for Cell Assay

  2026-08-06

  This article provides a scenario-driven, evidence-based guide for biomedical researchers and lab technicians seeking robust cell viability and proliferation data using Losartan (SKU B1072). It contextualizes APExBIO's Losartan as a reproducible angiotensin II receptor antagonist for cardiovascular and tumor microenvironment studies, offering validated protocol suggestions and vendor-selection advice.

• Open-Platform DLP Enables Precise 96-Well Hydrogel Printing

  2026-08-05

  The reference paper introduces a low-cost, open-platform digital light printer (OP-DLP) capable of high-throughput, spatially controlled hydrogel synthesis and localized light-activation in 96-well formats. This system overcomes reproducibility and scalability challenges in biomaterials research, offering new flexibility for cell signaling and surface patterning studies.

• Innovations in In Vitro Evaluation of Chlorambucil Responses

  2026-08-05

  Schwartz’s dissertation redefines in vitro drug evaluation by distinguishing growth inhibition from cell death in cancer assays, revealing that most agents—including nitrogen mustard alkylating agents like chlorambucil—exert complex, temporally distinct effects on both proliferation and viability. These insights enable more precise assay design and interpretation for cancer research applications.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page